Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

To be considered for this study, you would first need to sign a consent form, showing you understand and agree to take part. You must be at least 18 years old. A key requirement is that you have extensive-stage small-cell lung cancer and have recently finished 3 or 4 cycles of a specific chemotherapy (platinum-etoposide) along with durvalumab. Importantly, your cancer should not have progressed during this initial treatment, meaning it's either stable or has shrunk.

For your general health, you should be fairly active and able to look after yourself, with a good overall health score (doctors call this an 'ECOG performance status' of 0 or 1). Any side effects from your previous treatments, apart from hair loss or tiredness, should have largely gone away. Your body's organs, like your kidneys and liver, need to be working well. The study doctors would also need to confirm that your small-cell lung cancer is indeed extensive-stage.

Some things might mean you can't join. For example, if your cancer has spread to your brain and is causing symptoms, or if you've had certain serious reactions to immune-based treatments before. If you've had other cancers recently (unless they are very specific types) or have certain ongoing autoimmune conditions, you might also not be able to participate. The study also wouldn't be suitable if you've had a heart attack, serious heart failure, or a stroke within the last six months.

If you decide to take part, you would be randomly assigned to one of two groups, like flipping a coin. One group would receive tarlatamab plus durvalumab, and the other would receive durvalumab alone. This is done to make sure the comparison between the treatments is fair. Both medicines are usually given through an IV drip.

You would have regular visits to the hospital for your treatment and to have tests done. These tests would include blood samples, scans (like CT scans) to check on your cancer, and physical examinations. These visits help the study team monitor how you are responding to the treatment and check for any side effects. The exact schedule of visits and tests would be clearly explained by the study team.

The treatment period would continue as long as the treatment is working for you and you are tolerating it well. After the treatment phase, you would continue to have follow-up appointments to monitor your health and the long-term effects of the treatment. The total duration of your involvement could vary depending on how you respond to the treatment, but the study team would keep you fully informed every step of the way.